HLS HLS Therapeutics Inc.

2.565USD3.670 CAD · TSX-2.39%Mkt Cap: 79.36M USDP/E: —

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and inter…

Insiders, last 90 days27 buys
Institutional holders8 on file

Key Statistics

Company
Market Cap79.36M USD
Enterprise Value99.71M USD
Revenue (TTM)56.24M USD
Gross Profit45.42M USD
Net Income (TTM)-12.43M USD
Revenue/Share1.80 USD
Last Price2.565 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees85
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA40390B1094
Valuation
P/E (Trailing)—
P/E (Forward)-24.50
PEG—
EV/EBITDA8.38
EV/Revenue1.77
P/S2.02
P/B1.33
EPS (TTM)-0.31 USD
EPS (Forward)-0.15 USD
52W Range
0.000768% of range3.761
52W High3.761 USD
52W Low0.0007 USD
Profitability
Gross Margin81.83%
Oper. Margin-8.02%
EBITDA Margin30.24%
Profit Margin-22.40%
ROE-20.16%
ROA-9.04%
ROIC-3.97%
ROCE-3.69%
Growth
Revenue Growth3.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF17.13M USD
CapEx (TTM)1.70M USD
FCF Margin36.47%
FCF Yield25.84%
Net Debt28.17M USD
Net Debt/EBITDA1.66
Net Debt/FCF1.37
Balance Sheet
Debt/Equity0.81
Current Ratio1.05
Quick Ratio0.76
Book Value/Sh2.77 USD
Cash/Share0.44 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield1.57%
Payout Ratio0.00%
Ex-Div DateApr 27, 2023
Pay DateJun 15, 2023
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.158 USD
Upside (mean)+101.1%
Target Range2.989 USD – 8.440 USD
2.989+101.1% to mean8.440
# Analysts4
Ownership
Shares Out.30.94M
Float19.12M
Insiders0.56%
Institutions45.00%
Short Interest
Short Ratio0.0d
Short % Out.0.01%
Shares Short2.30K
Short (prev mo.)5.98K
Technical
SMA 502.872 (-10.7%)
SMA 2002.991 (-14.2%)
Beta0.71
S&P 52W Chg12.00%
Avg Vol (30d)49.67K
Avg Vol (10d)57.66K
Technical Indicators
RSI (14)33.0
MACD-0.1238
MACD Signal-0.0431
MACD Hist.-0.0807
BB Upper3.399 USD
BB Middle2.931 USD
BB Lower2.463 USD
BB Width31.93%
ATR (14)0.1373 USD
Vol Ratio (20d)2.21x

About HLS Therapeutics (TSE: HLS)

›

HLS Therapeutics (TSE: HLS) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 85 employees.

The shares were at 3.670 CAD on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 0.0010 CAD to 5.380 CAD: the price is 31.8% below the high and 366900.0% above the low.

Its market capitalisation is 113.53M CAD.

HLS Therapeutics reports return on equity of -20.2%, an operating margin of -8.0% and revenue up 3.5% year over year.

Its debt exceeds its cash by 28.17M USD, a debt-to-equity ratio of 0.81. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 7.379 CAD is 101.1% above the current price. The next earnings report is expected on 11 March 2027.